RANKL

Summary

Gene Symbol: RANKL
Description: TNF superfamily member 11
Alias: CD254, ODF, OPGL, OPTB2, RANKL, TNLG6B, TRANCE, hRANKL2, sOdf, tumor necrosis factor ligand superfamily member 11, TNF-related activation-induced cytokine, osteoclast differentiation factor, osteoprotegerin ligand, receptor activator of nuclear factor kappa B ligand, tumor necrosis factor (ligand) superfamily, member 11, tumor necrosis factor ligand 6B, tumor necrosis factor superfamily member 11
Species: human

Top Publications

  1. doi The skeleton: a multi-functional complex organ: the role of key signalling pathways in osteoclast differentiation and in bone resorption
    David J Mellis
    Musculoskeletal Research Programme, University of Aberdeen, Institute of Medical Sciences, Foresterhill, UK
    J Endocrinol 211:131-43. 2011
  2. ncbi Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
    D L Lacey
    Department of Pathology, Amgen, Inc, Thousand Oaks, California 91320 1789, USA
    Cell 93:165-76. 1998
  3. ncbi Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation
    M Nagai
    Department of Biochemistry, Iwate Medical University School of Dentistry, Uchimaru 19 1, Morioka, Iwate, 020 8505, Japan
    Biochem Biophys Res Commun 269:532-6. 2000
  4. ncbi Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease
    Nicola Giuliani
    Hematology Department of Internal Medicine and Biomedical Science, University of Parma, Parma, Italy
    Blood 100:4615-21. 2002
  5. ncbi Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL
    Cristina Sobacchi
    Institute of Biomedical Technologies, Consiglio Nazionale delle Ricerche, via F Cervi 93, 20090 Segrate, Italy
    Nat Genet 39:960-2. 2007
  6. ncbi Circulating profiles of osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand in post-menopausal women
    H Uemura
    Department of Preventive Medicine, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, 770 8503 Japan
    J Endocrinol Invest 31:163-8. 2008
  7. pmc TNFRSF11A and TNFSF11 are associated with age at menarche and natural menopause in white women
    Yan Lu
    Department of Surgery, Washington University in St Louis, St Louis, MO, USA
    Menopause 17:1048-54. 2010
  8. pmc Differential expression of the RANKL/RANK/OPG system is associated with bone metastasis in human non-small cell lung cancer
    Xianbo Peng
    Musculoskeletal Tumor Center, Peking University People s Hospital, Beijing, People s Republic of China
    PLoS ONE 8:e58361. 2013
  9. ncbi TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells
    B R Wong
    The Rockefeller University, New York, New York 10021, USA
    J Biol Chem 272:25190-4. 1997
  10. ncbi A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
    D M Anderson
    Department of Molecular Biology, Immunex Corporation, Seattle, Washington 98101, USA
    Nature 390:175-9. 1997

Research Grants

  1. Rajaram Gopalakrishnan; Fiscal Year: 2014
  2. Signal Transduction Mechanism of Osteoclast Differentiation
    Nandini Ghosh-Choudhury; Fiscal Year: 2013
  3. ATF4 and Osteoclastogenesis
    Guozhi Xiao; Fiscal Year: 2013
  4. Mechanism of ITAM Signal Regulation in Osteoclasts
    Mary Beth Humphrey; Fiscal Year: 2012
  5. Regulation of osteoblast number by PTH
    Robert L Jilka; Fiscal Year: 2013
  6. Alcohol-Induced Bone Resorption: The Role of Oxidative Stress
    Martin J J Ronis; Fiscal Year: 2013
  7. DANIELLE ARDEN VICTOR; Fiscal Year: 2014
  8. Paul R Odgren; Fiscal Year: 2014
  9. Ted A Bateman; Fiscal Year: 2015
  10. MECHANISMS OF POLARIZED SECRETION BY BONE CELLS
    Steven L Teitelbaum; Fiscal Year: 2013

Detail Information

Publications226 found, 100 shown here

  1. doi The skeleton: a multi-functional complex organ: the role of key signalling pathways in osteoclast differentiation and in bone resorption
    David J Mellis
    Musculoskeletal Research Programme, University of Aberdeen, Institute of Medical Sciences, Foresterhill, UK
    J Endocrinol 211:131-43. 2011
    ....
  2. ncbi Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation
    D L Lacey
    Department of Pathology, Amgen, Inc, Thousand Oaks, California 91320 1789, USA
    Cell 93:165-76. 1998
    ..OPG ligand (OPGL) binds to a unique hematopoeitic progenitor cell that is committed to the osteoclast lineage and stimulates the ..
  3. ncbi Cancer cells responsible for humoral hypercalcemia express mRNA encoding a secreted form of ODF/TRANCE that induces osteoclast formation
    M Nagai
    Department of Biochemistry, Iwate Medical University School of Dentistry, Uchimaru 19 1, Morioka, Iwate, 020 8505, Japan
    Biochem Biophys Res Commun 269:532-6. 2000
    A novel cDNA encoding a secreted form of osteoclast differentiation factor/tumor necrosis factor-related activation-induced cytokine (sODF/TRANCE, GenBank Accession No...
  4. ncbi Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease
    Nicola Giuliani
    Hematology Department of Internal Medicine and Biomedical Science, University of Parma, Parma, Italy
    Blood 100:4615-21. 2002
    ..the cross-talk between the critical osteoclastogenetic factor, receptor activator of nuclear factor-kappaB ligand (RANKL), and interferon gamma (IFN-gamma) that strongly suppresses osteoclastogenesis...
  5. ncbi Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL
    Cristina Sobacchi
    Institute of Biomedical Technologies, Consiglio Nazionale delle Ricerche, via F Cervi 93, 20090 Segrate, Italy
    Nat Genet 39:960-2. 2007
    ..Here we report mutations in the gene encoding RANKL (receptor activator of nuclear factor-KB ligand) in six individuals with autosomal recessive osteopetrosis whose ..
  6. ncbi Circulating profiles of osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand in post-menopausal women
    H Uemura
    Department of Preventive Medicine, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, 770 8503 Japan
    J Endocrinol Invest 31:163-8. 2008
    ..The aim of this study was to elucidate the detail profiles of circulating osteoprotegerin (OPG) and soluble receptor activator of nuclear factor kappaB ligand (sRANKL) in post-menopausal women...
  7. pmc TNFRSF11A and TNFSF11 are associated with age at menarche and natural menopause in white women
    Yan Lu
    Department of Surgery, Washington University in St Louis, St Louis, MO, USA
    Menopause 17:1048-54. 2010
    ..The onsets of menarche and menopause have a strong genetic basis. We tested two genes, TNFRSF11A (RANK) and TNFSF11 (RANKL), for their association with age at menarche (AM) and age at natural menopause (ANM).
  8. pmc Differential expression of the RANKL/RANK/OPG system is associated with bone metastasis in human non-small cell lung cancer
    Xianbo Peng
    Musculoskeletal Tumor Center, Peking University People s Hospital, Beijing, People s Republic of China
    PLoS ONE 8:e58361. 2013
    ..The RANKL/RANK/OPG system, which plays a pivotal role in bone remodeling by regulating osteoclast formation and activity, is ..
  9. ncbi TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells
    B R Wong
    The Rockefeller University, New York, New York 10021, USA
    J Biol Chem 272:25190-4. 1997
    A novel member of the tumor necrosis factor (TNF) cytokine family, designated TRANCE, was cloned during a search for apoptosis-regulatory genes using a somatic cell genetic approach in T cell hybridomas...
  10. ncbi A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function
    D M Anderson
    Department of Molecular Biology, Immunex Corporation, Seattle, Washington 98101, USA
    Nature 390:175-9. 1997
    ..of NF-kappaB), a new member of the TNFR family derived from dendritic cells, and the isolation of a RANK ligand (RANKL) by direct expression screening...
  11. pmc Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL
    H Yasuda
    Research Institute of Life Science, Snow Brand Milk Products Co, Ltd, 519 Ishibashi machi, Shimotsuga gun, Tochigi 329 0512, Japan
    Proc Natl Acad Sci U S A 95:3597-602. 1998
    ..We conclude that the membrane-bound protein is osteoclast differentiation factor (ODF), a long-sought ligand mediating an essential signal to osteoclast progenitors for their ..
  12. ncbi Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival
    L Lum
    Tri Institutional Cornell Rockefeller University Memorial Sloan Kettering Cancer Center, Training Program, New York, New York 10021, USA
    J Biol Chem 274:13613-8. 1999
    Tumor necrosis factor (TNF)-related activation-induced cytokine (TRANCE), a member of the TNF family, is a dendritic cell survival factor and is essential for osteoclastogenesis and osteoclast activation...
  13. ncbi Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand
    Y Y Kong
    Amgen Institute, Toronto, Ontario, Canada
    Nature 402:304-9. 1999
    ..remodelling and bone loss are controlled by a balance between the tumour necrosis factor family molecule osteoprotegerin ligand (OPGL) and its decoy receptor osteoprotegerin (OPG)...
  14. ncbi TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src
    B R Wong
    Laboratory of Immunology, Rockefeller University, New York, New York 10021, USA
    Mol Cell 4:1041-9. 1999
    b>TRANCE, a TNF family member, and its receptor, TRANCE-R, are critical regulators of dendritic cell and osteoclast function...
  15. ncbi Long-lived immature dendritic cells mediated by TRANCE-RANK interaction
    Isabelle Cremer
    Institut National de la Santé et de la Recherche Médicale INSERM U255, Centre de Recherches Biomedicales des Cordeliers, and Unité de Génétique Mycobactérienne, Institut Pasteur, Paris, France
    Blood 100:3646-55. 2002
    ..We have identified int-DCs that express both TRANCE (tumor necrosis factor-related activation-induced cytokine) and RANK (receptor activator of NF-kappaB) and have ..
  16. ncbi Expression of RANKL and OPG mRNA in periodontal disease: possible involvement in bone destruction
    D Liu
    Department of Orthopaedic Surgery, Queen Elizabeth II Medical Centre, UWA, WA, Australia
    Int J Mol Med 11:17-21. 2003
    ..Receptor activator of NF-kappaB ligand (RANKL), a novel TNF receptor-related protein is an important factor for osteoclast differentiation and activation...
  17. ncbi Catalytic properties of ADAM19
    Valerie Chesneau
    Cellular Biochemistry and Biophysics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Biol Chem 278:22331-40. 2003
    ..necrosis factor-alpha (TNF-alpha), TNF-related activation-induced cytokine (TRANCE, also referred to as osteoprotegerin ligand), and kit ligand-1 (KL-1) in vitro...
  18. pmc Role of RANKL-induced osteoclast formation and MMP-dependent matrix degradation in bone destruction by breast cancer metastasis
    T Ohshiba
    Department of Biochemistry, School of Pharmacy, Tokyo University of Pharmacy and Life Science, Tokyo, Japan
    Br J Cancer 88:1318-26. 2003
    ..Osteoclast differentiation regulated by the receptor activator of NF-kappaB ligand (RANKL) in osteoblasts and matrix degradation induced by matrix metalloproteinases (MMPs) are thought to be involved in ..
  19. ncbi RANKL expression is related to the differentiation state of human osteoblasts
    Gerald J Atkins
    Department of Orthopaedics and Trauma, University of Adelaide, Adelaide, South Australia, Australia
    J Bone Miner Res 18:1088-98. 2003
    ..Osteoblast differentiation markers were examined in relation to RANKL expression. RANKL expression was induced preferentially in immature cells...
  20. ncbi Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification
    Jens J Kaden
    First Department of Medicine Cardiology, Angiology, and Pneumology, Faculty of Clinical Medicine Mannheim, University of Heidelberg, Theordor Kutzer Ufer 1 3, 68167 Mannheim, Germany
    J Mol Cell Cardiol 36:57-66. 2004
    ..Receptor Activator of Nuclear factor kappaB Ligand" (RANKL) and osteoprotegerin (OPG) are members of a cytokine system involved in bone turnover and vascular calcification...
  21. ncbi Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Mönckeberg's sclerosis and atherosclerosis
    Michael Schoppet
    Department of Internal Medicine, Philipps University, Baldingerstrasse, D 35033 Marburg, Germany
    J Clin Endocrinol Metab 89:4104-12. 2004
    ....
  22. ncbi Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin
    Patricia Collin-Osdoby
    Department of Biology and Division of Bone and Mineral Research, Washington University, St Louis, MO 63130, USA
    Circ Res 95:1046-57. 2004
    ..One emerging area in vascular biology involves the RANKL/RANK/OPG system, molecules of the tumor necrosis factor-related family recently discovered to be critical ..
  23. ncbi Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma
    Pardeep Bhatia
    Center for Molecular Medicine, University of Connecticut Health Center, Farmington, Connecticut 06030, USA
    Clin Cancer Res 11:162-5. 2005
    During normal bone remodeling, the receptor activator of nuclear factor-kappaB (RANK) interacts with its ligand RANKL, which is present on pre-osteoclasts, resulting in bone resorption and initiation of new bone formation...
  24. ncbi MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL
    Conor C Lynch
    Department of Cancer Biology, Vanderbilt University, Nashville, Tennessee 37232, USA
    Cancer Cell 7:485-96. 2005
    ..MMP-7, which was produced by osteoclasts at the tumor-bone interface, was capable of processing RANKL to a soluble form that promoted osteoclast activation...
  25. ncbi Functional dissection of osteoprotegerin and its interaction with receptor activator of NF-kappaB ligand
    Lumelle A Schneeweis
    Department of Biochemistry and Biophysics and Johnson Research Foundation, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Biol Chem 280:41155-64. 2005
    ..Therefore, OPG dimer formation is required for the mechanism of inhibition of the RANK-L/RANK receptor interaction...
  26. ncbi IFN-gamma-producing human T cells directly induce osteoclastogenesis from human monocytes via the expression of RANKL
    Shigeru Kotake
    Institute of Rheumatology, Tokyo Women s Medical University, Tokyo, Japan
    Eur J Immunol 35:3353-63. 2005
    ..The concentration of soluble receptor activator of NF-kappaB ligand (RANKL) and IFN-gamma, and the amount of membrane type RANKL expressed on T cells, were measured by ELISA...
  27. ncbi Regulation of cancer cell migration and bone metastasis by RANKL
    D Holstead Jones
    IMBA, Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Dr Bohr Gasse 3, A 1030 Vienna, Austria
    Nature 440:692-6. 2006
    ..Here we show that the cytokine RANKL (receptor activator of NF-kappaB ligand) triggers migration of human epithelial cancer cells and melanoma cells ..
  28. ncbi Negative regulation of osteoclastogenesis by ectodomain shedding of receptor activator of NF-kappaB ligand
    Atsuhiko Hikita
    Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo 113 0033, USA
    J Biol Chem 281:36846-55. 2006
    Receptor activator of NF-kappaB ligand (RANKL) is a transmembrane glycoprotein that has an essential role in the development of osteoclasts...
  29. ncbi Receptor activator of nuclear factor-kappaB ligand (RANKL) expression in hepatocellular carcinoma with bone metastasis
    Atsushi Sasaki
    Department of Surgical Oncology, Medical Institute of Bioregulation, Kyushu University, 4546 Tsurumihara, Beppu, 874 0838, Japan
    Ann Surg Oncol 14:1191-9. 2007
    Although receptor activator of nuclear factor-kappaB ligand (RANKL) seems to be involved in the development of bone metastases in several malignant tumors, its role in hepatocellular carcinoma (HCC) has not been investigated.
  30. ncbi Soluble receptor activator of nuclear factor-kappa B ligand and risk for cardiovascular disease
    Stefan Kiechl
    Department of Neurology, Innsbruck Medical University, Anichstr 35, A 6020 Innsbruck, Austria
    Circulation 116:385-91. 2007
    Overexpression of receptor activator of nuclear factor-kappaB ligand (RANKL) is a prominent feature of vulnerable atherosclerotic lesions prone to rupture and was thought to contribute to the transition from a stable to an unstable ..
  31. pmc Biology of RANK, RANKL, and osteoprotegerin
    Brendan F Boyce
    Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, New York 14642, USA
    Arthritis Res Ther 9:S1. 2007
    The discovery of the receptor activator of nuclear factor-kappaB ligand (RANKL)/RANK/osteoprotegerin (OPG) system and its role in the regulation of bone resorption exemplifies how both serendipity and a logic-based approach can identify ..
  32. ncbi CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications
    Damaris Vega
    Department of Internal Medicine, Charles and Jane Pak Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390 8885, USA
    J Clin Endocrinol Metab 92:4514-21. 2007
    Receptor activator of nuclear factor-kappaB ligand (RANKL), receptor activator of nuclear factor-kappaB (RANK), and osteoprotegerin (OPG) play a central role in bone remodeling and disorders of mineral metabolism.
  33. ncbi Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis
    Jude R Canon
    Department of Oncology Research, Amgen Inc, Thousand Oaks, CA, USA
    Clin Exp Metastasis 25:119-29. 2008
    ..Receptor activator of NF-kappaB ligand (RANKL) is an essential mediator of osteoclast formation, function, and survival, and is blocked by a soluble decoy ..
  34. doi Intracellular and surface RANKL are differentially regulated in patients with ankylosing spondylitis
    Daniela Stupphann
    Department of Pathophysiology, Center of Physiology and Pathophysiology, Medical University of Vienna, Vienna, Austria
    Rheumatol Int 28:987-93. 2008
    ..T cells have been implicated as a source of receptor activator of NFkappaB ligand (RANKL) in inflammatory bone diseases...
  35. pmc Increased osteoclastic activity in acute Charcot's osteoarthropathy: the role of receptor activator of nuclear factor-kappaB ligand
    G Mabilleau
    Nuffield Department of Orthopaedic Surgery, Botnar Research Centre, University of Oxford, Oxford, UK
    Diabetologia 51:1035-40. 2008
    ..between patients with acute Charcot's osteoarthropathy and diabetic and healthy controls, and to determine the effect of the receptor activator of nuclear factor-kappaB ligand (RANKL) and its decoy receptor osteoprotegerin (OPG).
  36. doi Multiple genetic loci for bone mineral density and fractures
    Unnur Styrkarsdottir
    deCODE Genetics, Reykjavik, Iceland
    N Engl J Med 358:2355-65. 2008
    ..Bone mineral density influences the risk of osteoporosis later in life and is useful in the evaluation of the risk of fracture. We aimed to identify sequence variants associated with bone mineral density and fracture...
  37. doi Receptor activator of NF-kappaB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells
    Valerie A Odero-Marah
    Molecular Urology and Therapeutics Program, Department of Urology and Winship Cancer Institute, Emory University School of Medicine, 1365B Clifton Road, NE, Atlanta, GA 30322, USA
    Cell Res 18:858-70. 2008
    ..markers of vimentin and N-cadherin in addition to elevated levels of Receptor Activator of NF-kappaB Ligand (RANKL)...
  38. doi New sequence variants associated with bone mineral density
    Unnur Styrkarsdottir
    deCODE Genetics, Reykjavik, Iceland
    Nat Genet 41:15-7. 2009
    ..Furthermore, nonsynonymous SNPs in the C17orf53, LRP4, ADAM19 and IBSP genes were suggestively associated with bone density...
  39. doi Osteoprotegerin and RANKL differentially regulate angiogenesis and endothelial cell function
    Joseph S McGonigle
    Department of Bioengineering, University of Washington, Seattle, WA, USA
    Angiogenesis 12:35-46. 2009
    ..In this study, we assessed the role of OPG and its ligands, receptor activator of nuclear factor-kappaB ligand (RANKL) and tumor necrosis factor-related apoptosis inducing ligand (TRAIL), in microvessel formation using the rat ..
  40. doi Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: a nested case-control approach in the prospective EPIC-Norfolk population study 1993-2003
    Anne G Semb
    Department of Rheumatology, Diakonhjemmet Hospital, N 0319 Oslo, Norway
    Arterioscler Thromb Vasc Biol 29:975-80. 2009
    ..association between serum levels of osteoprotegerin (OPG) and receptor activator of nuclear factor-kappaB ligand (RANKL) and future coronary artery disease (CAD) in apparently healthy individuals...
  41. pmc Association analyses of RANKL/RANK/OPG gene polymorphisms with femoral neck compression strength index variation in Caucasians
    Shan Shan Dong
    Key Laboratory of Biomedical Information Engineering, Ministry of Education and Institute of Molecular Genetics, School of Life Science and Technology, Xi an Jiaotong University, Xi an 710049, People s Republic of China
    Calcif Tissue Int 85:104-12. 2009
    ..activator of the nuclear factor-kappaB ligand/receptor activator of the nuclear factor-kappaB/osteoprotegerin (RANKL/RANK/OPG) pathway in the regulation of bone remodeling, we tested the associations between RANKL/RANK/OPG ..
  42. ncbi Receptor activator of nuclear factor kappa B ligand in an experimental intervertebral disc degeneration
    Z Mackiewicz
    COXA Hospital for Joint Replacement, Tampere, Finland
    Clin Exp Rheumatol 27:299-306. 2009
    This study was designed to clarify the role of the receptor activator of nuclear factor kappa B ligand (RANKL) in the process of discus degeneration and spondylarthrosis...
  43. doi A novel function of CXCL13 to stimulate RANK ligand expression in oral squamous cell carcinoma cells
    Sambandam Yuvaraj
    Charles P Darby Children s Research Institute, Charleston, SC 29425, USA
    Mol Cancer Res 7:1399-407. 2009
    ..Here in, we show that recombinant hCXCL13 treatment of OSCC cells stimulates (5-fold) RANK ligand (RANKL), a critical bone resorbing osteoclastogenic factor expression...
  44. pmc Control of RANKL gene expression
    CHARLES A O'BRIEN
    Center for Osteoporosis and Metabolic Bone Diseases, University of Arkansas for Medical Sciences, and Central Arkansas Veterans Healthcare System, Little Rock, AR 72205, USA
    Bone 46:911-9. 2010
    ..Only one of these cytokines, receptor activator of NFkappaB ligand (RANKL), is absolutely essential for osteoclast formation throughout life and is thus expressed by all cell types that ..
  45. doi Central control of fever and female body temperature by RANKL/RANK
    Reiko Hanada
    IMBA, Institute of Molecular Biotechnology of the Austrian Academy of Sciences, 1030 Vienna, Austria
    Nature 462:505-9. 2009
    Receptor-activator of NF-kappaB ligand (TNFSF11, also known as RANKL, OPGL, TRANCE and ODF) and its tumour necrosis factor (TNF)-family receptor RANK are essential regulators of bone remodelling, lymph node organogenesis and formation of ..
  46. doi Genetic variations in genes encoding RANK, RANKL, and OPG in rheumatoid arthritis: a case-control study
    Gunter Assmann
    Internal Medicine I and José Carreras Research Centre, University of Saarland Medical School, Homburg Saar, Germany
    J Rheumatol 37:900-4. 2010
    ..Genetic variations in the genes coding for RANK, RANK ligand (RANKL), and OPG are thought to play roles in the susceptibility to RA.
  47. doi Involvement of integrin up-regulation in RANKL/RANK pathway of chondrosarcomas migration
    Chin Jung Hsu
    School of Chinese Medicine, China Medical University, Taichung, Taiwan
    J Cell Biochem 111:138-47. 2010
    ..Receptor activator of nuclear factor-kappaB ligand (RANKL) and its receptor, RANK, play a key roles in osteoclastogenesis and tumor metastasis...
  48. pmc PKA-induced receptor activator of NF-kappaB ligand (RANKL) expression in vascular cells mediates osteoclastogenesis but not matrix calcification
    Wendy Tseng
    Department of Physiological Science, University of California, Los Angeles, California 90095, USA
    J Biol Chem 285:29925-31. 2010
    ..osteoblast-production of osteoclast regulating cytokines, including receptor-activator of nuclear κB ligand (RANKL) and interleukins...
  49. doi RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis
    Eva Gonzalez-Suarez
    Department of Hematology Oncology Research, Amgen Inc, Seattle, Washington 98119, USA
    Nature 468:103-7. 2010
    RANK ligand (RANKL), a TNF-related molecule, is essential for osteoclast formation, function and survival through interaction with its receptor RANK...
  50. pmc Genome-wide association meta-analysis of cortical bone mineral density unravels allelic heterogeneity at the RANKL locus and potential pleiotropic effects on bone
    Lavinia Paternoster
    University of Bristol, Bristol, UK
    PLoS Genet 6:e1001217. 2010
    ..The rs1021188 SNP (near RANKL) was associated with BMD(C) in all cohorts (overall p = 2×10(-14), n = 5739)...
  51. pmc Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling
    Wei Tan
    Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, University of California San Diego School of Medicine, La Jolla, California 92093, USA
    Nature 470:548-53. 2011
    ..upregulation of two tumour-necrosis-factor family members: receptor activator of nuclear factor-κB (RANK) ligand (RANKL) and lymphotoxin. But the source of RANKL and its role in metastasis have not been established...
  52. doi RANKL increases migration of human lung cancer cells through intercellular adhesion molecule-1 up-regulation
    Li Mien Chen
    Center of General Education, Central Taiwan University of Science and Technology, Taichung, Taiwan
    J Cell Biochem 112:933-41. 2011
    ..Receptor activator of nuclear factor-κB ligand (RANKL) and its receptor, RANK, play a key role in osteoclastogenesis and tumor metastasis...
  53. pmc Genome-wide association study using extreme truncate selection identifies novel genes affecting bone mineral density and fracture risk
    Emma L Duncan
    University of Queensland Diamantina Institute, University of Queensland, Princess Alexandra Hospital, Brisbane, Australia
    PLoS Genet 7:e1001372. 2011
    ..In addition to identifying further genes associated with BMD, this study confirms the efficiency of extreme-truncate selection designs for quantitative trait association studies...
  54. pmc WNT16 influences bone mineral density, cortical bone thickness, bone strength, and osteoporotic fracture risk
    Hou Feng Zheng
    Department of Medicine, Human Genetics, McGill University, Montreal, Canada
    PLoS Genet 8:e1002745. 2012
    ..Natural variation in humans and targeted disruption in mice demonstrate that WNT16 is an important determinant of CBT, BMD, bone strength, and risk of fracture...
  55. ncbi Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer
    Sioned Owen
    Metastasis and Angiogenesis Research Group, Department of Surgery, Cardiff University School of Medicine, Cardiff, CF14 4XN, U K
    Anticancer Res 33:199-206. 2013
    ..Receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) are a group of important regulators for osteoclast differentiation and activation...
  56. pmc Genetic determinants of trabecular and cortical volumetric bone mineral densities and bone microstructure
    Lavinia Paternoster
    MRC Centre for Causal Analyses in Translational Epidemiology, University of Bristol, Bristol, United Kingdom
    PLoS Genet 9:e1003247. 2013
    ..replication (n = 1,052) identified genetic variants in four separate loci reaching genome-wide significance (RANKL, rs1021188, p = 3.6×10⁻¹⁴; LOC285735, rs271170, p = 2.7×10⁻¹²; OPG, rs7839059, p = 1...
  57. pmc Activated human T cells express alternative mRNA transcripts encoding a secreted form of RANKL
    N C Walsh
    St Vincent s Institute of Medical Research, Melbourne, Victoria, Australia
    Genes Immun 14:336-45. 2013
    Receptor activator of nuclear factor-kappaB-ligand (RANKL), encoded by the gene TNFSF11, is required for osteoclastogenesis, and its expression is upregulated in pathologic bone loss...
  58. pmc Convergent RANK- and c-Met-mediated signaling components predict survival of patients with prostate cancer: an interracial comparative study
    Peizhen Hu
    Uro Oncology Research Program, Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California, United States of America
    PLoS ONE 8:e73081. 2013
    We reported (PLoS One 6 (12):e28670, 2011) that the activation of c-Met signaling in RANKL-overexpressing bone metastatic LNCaP cell and xenograft models increased expression of RANK, RANKL, c-Met, and phosphorylated c-Met, and mediated ..
  59. pmc TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor
    B R Wong
    Laboratory of Immunology, The Rockefeller University, New York 10021, USA
    J Exp Med 186:2075-80. 1997
    b>TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine) is a new member of the TNF family that is induced upon T cell receptor engagement and activates c-Jun N-terminal kinase (JNK) after interaction with its putative ..
  60. ncbi Serum levels of OPG, RANKL and RANKL/OPG ratio in newly-diagnosed patients with multiple myeloma. Clinical correlations
    Veselina Goranova-Marinova
    Clinic of Hematology, University Hospital Sv Georgi Plovdiv, Plovdiv, Bulgaria
    Haematologica 92:1000-1. 2007
    Serum levels of OPG and RANKL and their clinical correlations were analyzed in 66 newly-diagnosed patients with multiple myeloma (MM)...
  61. ncbi Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women
    Jung Gu Kim
    Department of Obstetrics and Gynecology, College of Medicine, and Clinical Research Institute, Seoul National University Hospital, Seoul, Korea
    Menopause 14:913-8. 2007
    ..association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL (sRANKL) levels, and bone mineral density (BMD) in Korean ..
  62. doi Genetic variation in the RANKL/RANK/OPG signaling pathway is associated with bone turnover and bone mineral density in men
    Delnaz Roshandel
    Arthritis Research UK, Epidemiology Unit, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK
    J Bone Miner Res 25:1830-8. 2010
    The aim of this study was to determine if single-nucleotide polymorphisms (SNPs) in RANKL, RANK, and OPG influence bone turnover and bone mineral density (BMD) in men. Pairwise tag SNPs (r(2) > or = 0...
  63. doi No influence of OPG and its ligands, RANKL and TRAIL, on proliferation and regulation of the calcification process in primary human vascular smooth muscle cells
    Malene Olesen
    Department of Cardiovascular and Renal Research, Institute of Molecular Medicine, University of Southern Denmark, Denmark
    Mol Cell Endocrinol 362:149-56. 2012
    The aim of this study was to examine the effects of the OPG-RANKL-TRAIL system on proliferation, regulation of calcification-associated genes and calcification of human vascular smooth muscle cells (HVSMCs)...
  64. ncbi Functional role for heat shock factors in the transcriptional regulation of human RANK ligand gene expression in stromal/osteoblast cells
    Jennifer L Roccisana
    Department of Medicine Division of Hematology, The University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
    J Biol Chem 279:10500-7. 2004
    RANK Ligand (RANKL) is a critical osteoclastogenic factor that is expressed on stromal cells and osteoblasts. Most resorption stimuli induce osteoclast formation by modulating RANKL gene expression in marrow stromal/osteoblast cells...
  65. ncbi RANK and RANKL expression as markers of dendritic cell-T cell interactions in paired samples of rheumatoid synovium and lymph nodes
    Guillaume Page
    INSERM U403, Unité Mixte Hospices Civils de Lyon BioMérieux, and Hôpital Edouard Herriot, France
    Arthritis Rheum 52:2307-12. 2005
    The RANK/RANKL pathway is critical in bone destruction in conditions such as rheumatoid arthritis (RA)...
  66. ncbi Variation in genes involved in the RANKL/RANK/OPG bone remodeling pathway are associated with bone mineral density at different skeletal sites in men
    Yi Hsiang Hsu
    Program for Population Genetics, Harvard School of Public Health, 665 Huntington Avenue, FXB 101, Boston, MA, USA
    Hum Genet 118:568-77. 2006
    In order to assess the contribution of polymorphisms in the RANKL (TNFSF11), RANK (TNFRSF11A) and OPG (TNFRSF11B) genes to variations in bone mineral density (BMD), a population-based cohort with 1,120 extreme low hip BMD cases or ..
  67. pmc Multiple enhancer regions located at significant distances upstream of the transcriptional start site mediate RANKL gene expression in response to 1,25-dihydroxyvitamin D3
    Sungtae Kim
    Department of Biochemistry, University of Wisconsin Madison, 433 Babcock Drive, Madison, WI 53706, USA
    J Steroid Biochem Mol Biol 103:430-4. 2007
    One of the primary regulators of receptor activator of NF-kappaB ligand (RANKL) is 1,25-dihydoxyvitamin D(3) (1,25(OH)(2)D(3))...
  68. doi Allelic variations of RANKL/OPG signaling system are related to bone mineral density and in vivo gene expression
    Istvan Takacs
    1st Department of Internal Medicine, Semmelweis University, Koranyi S u 2 a, Budapest H 1083, Hungary
    Eur J Endocrinol 162:423-31. 2010
    Receptor activator of nuclear factor-kappaB ligand/osteoprotegerin (RANKL/OPG) signaling system plays a crucial role in the regulation of bone resorption...
  69. ncbi Cooperation of TNF family members CD40 ligand, receptor activator of NF-kappa B ligand, and TNF-alpha in the activation of dendritic cells and the expansion of viral specific CD8+ T cell memory responses in HIV-1-infected and HIV-1-uninfected individuals
    Qigui Yu
    Clinical Sciences Division, Medical Sciences Building, University of Toronto, Toronto, Ontario, Canada M5S 1A8
    J Immunol 170:1797-805. 2003
    ..the ability of three TNF superfamily molecules, CD40 ligand (CD40L), receptor activator of NF-kappaB ligand (RANKL), and TNF-alpha, to expand ex vivo EBV-specific CTL responses in healthy human individuals and ex vivo HIV-1-..
  70. ncbi Regulation of osteoclastogenesis by three human RANKL isoforms expressed in NIH3T3 cells
    Junko Suzuki
    Department of Pathology and Immunology, Aging and Developmental Science, Graduate School, Tokyo Medical and Dental University, 113 8519, Tokyo, Japan
    Biochem Biophys Res Commun 314:1021-7. 2004
    ..Three human RANKL isoforms, hRANKL1, hRANKL2, and hRANKL3, were identified...
  71. ncbi Identification of an alternatively spliced variant of Ca2+-promoted Ras inactivator as a possible regulator of RANKL shedding
    Atsuhiko Hikita
    Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, 7 3 1 Hongo, Bunkyo ku, Tokyo 113 0033, Japan
    J Biol Chem 280:41700-6. 2005
    The receptor activator of NF-kappaB ligand (RANKL), a critical regulator of osteoclastogenesis, is synthesized as a membrane-anchored protein and cleaved into a soluble form by ectodomain shedding...
  72. pmc OPG and RANK polymorphisms are both associated with cortical bone mineral density: findings from a metaanalysis of the Avon longitudinal study of parents and children and gothenburg osteoporosis and obesity determinants cohorts
    L Paternoster
    Medical Research Council Centre for Causal Analyses in Translational Epidemiology, Department of Social Medicine, University of Bristol, Oakfield House, Oakfield Grove, Bristol BS8 2BN, United Kingdom
    J Clin Endocrinol Metab 95:3940-8. 2010
    ..Several single-nucleotide polymorphisms (SNPs) have been reliably associated with areal bone mineral density (aBMD) in genome-wide association studies of mostly older subjects...
  73. ncbi Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families
    T Suda
    Department of Biochemistry, School of Dentistry, Showa University, Tokyo, Japan
    Endocr Rev 20:345-57. 1999
    ..RANKL, which has also been called ODF, TRANCE, or OPGL, is a member of the TNF ligand family...
  74. ncbi Production of IL-7 is increased in ovariectomized mice, but not RANKL mRNA expression by osteoblasts/stromal cells in bone, and IL-7 enhances generation of osteoclast precursors in vitro
    Takuya Sato
    Division of Oral Anatomy, Department of Human Development and Fostering, Meikai University School of Dentistry, 1 1 Keyaki dai, Sakado, 350 0283, Japan
    J Bone Miner Metab 25:19-27. 2007
    ..However, the contribution of increased RANKL produced by osteoblasts/stromal cells to increase osteoclastogenesis in a mouse model of estrogen-deficient ..
  75. ncbi Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor fu
    D Chikazu
    Department of Orthopedic Surgery, Graduate School of Medicine, University of Tokyo, Japan
    J Bone Miner Res 16:2074-81. 2001
    ..FGF-2 (> or = 10(-9) M) stimulated receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor (RANKL/ODF) messenger RNA (mRNA) expression from 2 h to 7 days in cultured osteoblasts...
  76. ncbi Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway
    Xiang Hang Luo
    Institute of Endocrinology and Metabolism, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China
    J Bone Miner Res 21:1648-56. 2006
    Our study indicates that recombinant adiponectin induced RANKL and inhibited OPG expression in human osteoblasts through the AdipoR1/p38 MAPK pathway, and these responses contributed to the adiponectin-induced osteoclasts formation in ..
  77. ncbi RANK ligand signaling modulates the matrix metalloproteinase-9 gene expression during osteoclast differentiation
    Kumaran Sundaram
    Charles P Darby Children s Research Institute, 173 Ashley Avenue, Charleston, SC 29425, USA
    Exp Cell Res 313:168-78. 2007
    Osteoclast differentiation is tightly regulated by receptor activator of NF-kappaB ligand (RANKL) signaling...
  78. ncbi Dominant negative N-cadherin inhibits osteoclast differentiation by interfering with beta-catenin regulation of RANKL, independent of cell-cell adhesion
    Chan Soo Shin
    Department of Internal Medicine, Seoul National University College of Medicine, Korea
    J Bone Miner Res 20:2200-12. 2005
    ..NCadDeltaC inhibited beta-catenin/TCF signaling, resulting in decreased RANKL expression, which could contribute to the reduced osteoclast formation.
  79. ncbi RANKL coordinates cell cycle withdrawal and differentiation in osteoclasts through the cyclin-dependent kinase inhibitors p27KIP1 and p21CIP1
    Uma Sankar
    Department of Molecular Genetics, The Ohio State University, Columbus, Ohio 43210, USA
    J Bone Miner Res 19:1339-48. 2004
    The coordination of cell cycle progression and osteoclast differentiation by RANKL signaling was studied...
  80. doi Simvastatin inhibits osteoclast differentiation induced by bone morphogenetic protein-2 and RANKL through regulating MAPK, AKT and Src signaling
    Misuzu Yamashita
    Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2 5 1 Shikata cho, Kitaku, Okayama City, 700 8558, Japan
    Regul Pept 162:99-108. 2010
    ..Here we examined roles of simvastatin in osteoclast function and differentiation induced by RANKL and BMP-2 using mouse macrophage-like MLC-6 cells and human osteoclast precursor cells...
  81. doi JNK/c-Jun signaling mediates an anti-apoptotic effect of RANKL in osteoclasts
    Fumiyo Ikeda
    Department of Biochemistry, Osaka University Graduate School of Dentistry, Osaka, Japan
    J Bone Miner Res 23:907-14. 2008
    b>RANKL is known to be important not only for differentiation and activation of osteoclasts but also for their survival. Experimentally, apoptosis of osteoclasts is rapidly induced by the deprivation of RANKL...
  82. ncbi Cell-based assay strategy for identification of motif-specific RANK signaling pathway inhibitors
    Taosheng Chen
    Lead Discovery and Profiling, Bristol Myers Squibb Company, Wallingford, CT 06492, USA
    Assay Drug Dev Technol 4:473-82. 2006
    ..Almost a decade ago, the receptor activator of nuclear factor-kappaB (RANK) ligand (RANKL) was identified as an essential factor required for osteoclast formation...
  83. ncbi RANKL regulates Fas expression and Fas-mediated apoptosis in osteoclasts
    Xiaojun Wu
    Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama 35294 0007, USA
    J Bone Miner Res 20:107-16. 2005
    Osteoclast apoptosis is an influential determinant of osteoclast bone-resorbing activity. RANKL, a critical factor for osteoclastogenesis, is also important in osteoclast survival...
  84. ncbi Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation
    Karl D Häusler
    Bone, Joint, and Cancer Unit, St Vincent s Institute of Medical Research, Fitzroy, Victoria, Australia
    J Bone Miner Res 19:1873-81. 2004
    ..In studying the mechanism of action for sFRP-1, we found that sFRP-1 could bind recombinant RANKL. These results suggest potential cross-talk between Wnt and RANKL pathways.
  85. ncbi RANKL and vascular endothelial growth factor (VEGF) induce osteoclast chemotaxis through an ERK1/2-dependent mechanism
    Kim Henriksen
    Nordic Bioscience, Herlev DK 2730, Denmark
    J Biol Chem 278:48745-53. 2003
    ..We show that RANKL and VEGF, two cytokines known to be present in bone, possess chemotactic properties toward osteoclasts cultured in ..
  86. pmc RANKL increases the level of Mcl-1 in osteoclasts and reduces bisphosphonate-induced osteoclast apoptosis in vitro
    Karen A Sutherland
    Bone and Musculoskeletal Research Programme, School of Medicine and Dentistry, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, UK
    Arthritis Res Ther 11:R58. 2009
    ..of bisphosphonates to induce osteoclast apoptosis and inhibit bone resorption in vitro is influenced by the cytokine receptor activator of nuclear factor-kappa B ligand (RANKL), an important mediator of inflammation-induced bone loss.
  87. ncbi Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors
    V Shalhoub
    Department of Pathology, Amgen Inc, Thousand Oaks, California 91320, USA
    J Cell Biochem 72:251-61. 1999
    Osteoprotegerin (OPG) and its ligand (OPGL) negatively and positively regulate osteoclastogenesis in the mouse. OPG inhibits osteoclastogenesis by sequestering its ligand, OPGL, the osteoclast differentiation and activation factor...
  88. ncbi Induction of osteoclast differentiation by Runx2 through receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin regulation and partial rescue of osteoclastogenesis in Runx2-/- mice by RANKL transgene
    Hirayuki Enomoto
    Department of Molecular Medicine, Osaka University Graduate School of Medicine, Suita, Osaka 565 0871, Japan
    J Biol Chem 278:23971-7. 2003
    Receptor activator of nuclear factor-kappaB ligand (RANKL), osteoprotegerin (OPG), and macrophage-colony stimulating factor play essential roles in the regulation of osteoclastogenesis...
  89. ncbi RANK signaling is not required for TNFalpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis
    Ping Li
    Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York 14642, USA
    J Bone Miner Res 19:207-13. 2004
    To address the controversy of whether TNFalpha can compensate for RANKL in osteoclastogenesis in vivo, we used a TNFalpha-induced animal model of inflammatory arthritis and blocked RANKL/RANK signaling...
  90. ncbi Connection between B lymphocyte and osteoclast differentiation pathways
    N Manabe
    Department of Orthopaedic Surgery and Cardiovascular Medicine, Faculty of Medicine, University of Tokyo, Tokyo, Japan
    J Immunol 167:2625-31. 2001
    ..Recently the TNF family molecule osteoclast differentiation factor/receptor activator of NF-kappaB ligand (ODF/RANKL) was identified as a key membrane-associated ..
  91. ncbi A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro
    J M Quinn
    The University of Melbourne, Department of Medicine and St Vincent s Institute of Medical Research, Fitzroy, Australia
    Endocrinology 139:4424-7. 1998
    ..provided by murine osteoblasts and marrow-derived stromal cells is now known to be mediated by osteoclast differentiation factor (ODF), a membrane-bound tumor necrosis factor-related ligand...
  92. ncbi Selective blockade of voltage-gated potassium channels reduces inflammatory bone resorption in experimental periodontal disease
    Paloma Valverde
    Department of Oral and Developmental Biology, Harvard Medical School and Harvard School of Dental Medicine, Boston, Massachusetts, USA
    J Bone Miner Res 19:155-64. 2004
    ..Systemic administration of kaliotoxin abrogated the bone resorption in conjunction with decreased RANKL mRNA expression by T-cells in gingival tissue...
  93. ncbi Potassium channel-blockers as therapeutic agents to interfere with bone resorption of periodontal disease
    P Valverde
    Tufts University School of Dental Medicine, One Kneeland Street, Boston, MA 02111, USA
    J Dent Res 84:488-99. 2005
    ..T- and B-cells, necessary to control immunological interactive networks and to accelerate bone resorption by RANKL-dependent and -independent mechanisms...
  94. ncbi Evidence that genetic deletion of the TNF receptor p60 or p80 in macrophages modulates RANKL-induced signaling
    Yasunari Takada
    Cytokine Research Laboratory, Department of Experimental Therapeutics, Box 143, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 104:4113-21. 2004
    ..current report, we investigated the possibility of a cross-talk between receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor alpha (TNF-alpha) using macrophage cell lines derived from wild-type mice and from mice ..
  95. ncbi Immune response: the key to bone resorption in periodontal disease
    Martin A Taubman
    Department of Immunology, The Forsyth Institute, Boston, MA 02115, USA
    J Periodontol 76:2033-41. 2005
    ..Receptor activator of nuclear factor kappaB ligand (RANKL), a critical osteoclast differentiation factor, is expressed on T lymphocytes in human periodontal disease as determined by immunohistochemical and ..
  96. ncbi RANKL inhibition: a novel strategy to decrease femoral head deformity after ischemic osteonecrosis
    Harry K W Kim
    Center for Research in Skeletal Development and Pediatric Orthopaedics, Shriners Hospitals for Children, FL 33612, USA
    J Bone Miner Res 21:1946-54. 2006
    ..b>RANKL inhibition through exogenous osteoprotegerin administration significantly decreased pathologic bone resorption and ..
  97. pmc Colony-stimulating factor-1 (CSF-1) directly inhibits receptor activator of nuclear factor-{kappa}B ligand (RANKL) expression by osteoblasts
    Y Wittrant
    South Texas Veteran s Health Care System, Audi L Murphy Division, University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, Texas 78229, USA
    Endocrinology 150:4977-88. 2009
    ..via the c-fms receptor (CSF-1R) and, in combination with receptor activator of nuclear factor-kappaB ligand (RANKL), leads to the formation of mature osteoclasts...
  98. ncbi Effects of arachidonic acid, docosahexaenoic acid, prostaglandin E(2) and parathyroid hormone on osteoprotegerin and RANKL secretion by MC3T3-E1 osteoblast-like cells
    Magdalena Coetzee
    Department of Physiology, University of Pretoria, PO Box 2034, Pretoria 0001, South Africa
    J Nutr Biochem 18:54-63. 2007
    ..Cell-to-cell contact between osteoblasts and osteoclast precursors is required for osteoclast formation. RANKL (receptor activator of nuclear factor-kappaB ligand) expressed on osteoblastic cell membranes stimulates ..
  99. doi RANKL inhibition with osteoprotegerin increases bone strength by improving cortical and trabecular bone architecture in ovariectomized rats
    Michael S Ominsky
    Metabolic Disorders Research, Amgen, Thousand Oaks, California, USA
    J Bone Miner Res 23:672-82. 2008
    Ovariectomy (OVX) results in bone loss caused by increased bone resorption. RANKL is an essential mediator of bone resorption...
  100. doi Evidences of the cooperative role of the chemokines CCL3, CCL4 and CCL5 and its receptors CCR1+ and CCR5+ in RANKL+ cell migration throughout experimental periodontitis in mice
    Carlos Eduardo Repeke
    Department of Biological Sciences, School of Dentistry of Bauru, Sao Paulo University, FOB USP, Al Octávio Pinheiro Brisola, 9 75 CEP 17012 901, Bauru, SP, Brazil
    Bone 46:1122-30. 2010
    ..severe alveolar bone resorption, associated with a high expression of CCL3 and the migration of CCR5+, CCR1+ and RANKL+ cells to periodontal tissues...
  101. ncbi Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responses
    Marina Stolina
    Department of Metabolic Disorders, Amgen Inc, Thousand Oaks, CA 91320, USA
    J Immunol 179:7497-505. 2007
    Receptor activator of NF-kappaB ligand (RANKL) is an essential mediator of osteoclast formation, function, and survival. The effects of RANKL are inhibited by a soluble decoy receptor called osteoprotegerin (OPG)...

Research Grants79

  1. Rajaram Gopalakrishnan; Fiscal Year: 2014
    ..Further, we show that exogenous BMP2 increases pSmad1/5/8 levels in WT osteoclasts and also enhances RANKL stimulated osteoclast differentiation...
  2. Signal Transduction Mechanism of Osteoclast Differentiation
    Nandini Ghosh-Choudhury; Fiscal Year: 2013
    ..osteoblastic expression of another critical osteoclastogenic protein, the receptor activator of NF:B ligand (RANKL) and activates nuclear factor of activated T cells c1 (NFATc1), a master regulator of osteoclastogenesis...
  3. ATF4 and Osteoclastogenesis
    Guozhi Xiao; Fiscal Year: 2013
    ..Furthermore, ATF4 directs RANKL-dependent gene expression of NFATc1, a master regulator of OCL differentiation...
  4. Mechanism of ITAM Signal Regulation in Osteoclasts
    Mary Beth Humphrey; Fiscal Year: 2012
    ..We will determine the role of SHIP1 in negatively regulating DAP12 downstream of MCSF, RANKL, and integrin stimulation...
  5. Regulation of osteoblast number by PTH
    Robert L Jilka; Fiscal Year: 2013
    ..PTH increases the formation of osteoclasts by stimulating the expression of receptor-activator of NFkB-ligand (RANKL). However, the PTH-generated signals stimulating the development of osteoblasts are poorly understood...
  6. Alcohol-Induced Bone Resorption: The Role of Oxidative Stress
    Martin J J Ronis; Fiscal Year: 2013
    ..In the rat model, increased bone resorption was accompanied by increased expression of RANKL in bone...
  7. DANIELLE ARDEN VICTOR; Fiscal Year: 2014
    ..factors that have been shown to affect osteoblastogenesis (Wnt10b, BMP6, and PDGF BB) or osteoclastogenesis (RANKL, OPG, and M-CSF)...
  8. Paul R Odgren; Fiscal Year: 2014
    ..Similarities include 1) up- regulation of mRNA and protein upon stimulation of OC precursors by RANKL;2) predicted topology of transmembrane (TM) helices;3) presence of a DC-STAMP family consensus sequence in the C-..
  9. Ted A Bateman; Fiscal Year: 2015
    ..Existing therapies for osteoporosis and other disorders (e.g., the antiresorptive zoledronate, RANKL-blocking osteoprotegerin (OPG), TNFa binding protein [TNFbp], IL-1 receptor antagonist [IL-1ra], and a TGF[..
  10. MECHANISMS OF POLARIZED SECRETION BY BONE CELLS
    Steven L Teitelbaum; Fiscal Year: 2013
    ..We find that RANKL-mediated organization of the OC cytoskeleton, and the cell's capacity to resorb bone, involve activation of ..
  11. Bin Wang; Fiscal Year: 2015
    ..do not express PTH1R, and the response to PTH is primarily mediated by receptor activator of NFkB ligand (RANKL). The engagement of RANKL binding to RANK leads to induction of gene expression involved in osteoclastogenesis...
  12. Regulation of Myeloid Development and Function by II-4
    Achsah D Keegan; Fiscal Year: 2010
    ..We took advantage of a simplified system using recombinant RANKL to directly test the effect of IL-4 on osteoclasts...
  13. Role of Osteoactivin in Osteoclasts
    MATILDA HAN CHIN SHENG; Fiscal Year: 2010
    ..murine osteoclast precursors will be used to determine if siRNA-mediated OA gene knockdown interferes with the RANKL-induced differentiation of osteoclasts as measured by osteoclast size, number of nuclei per osteoclast, migration, ..
  14. CHARLES A O'BRIEN; Fiscal Year: 2016
    ..by which stromal cells support osteoclast differentiation is expression of receptor activator of NF(B ligand (RANKL)...
  15. IGF-1 MEDIATES THE ANABOLIC EFFECTS OF PTH ON BONE
    DANIEL DAVID BIKLE; Fiscal Year: 2012
    ..The ability of PTH to stimulate bone resorption is mediated primarily by induction of RANKL and suppression of OPG by osteoblasts resulting in the differentiation and subsequent activation of osteoclast ..
  16. Yasuyoshi Ueki; Fiscal Year: 2014
    ..to macrophage colony stimulating factor (M-CSF) and receptor activator of nuclear factor-KB (NF-KB) ligand (RANKL), respectively...
  17. Effect of MIP-1 delta on Osteoclast Development and Pathological Bone Resorption
    Scott L Kominsky; Fiscal Year: 2010
    ..pathological bone loss by enhancing stimulation of key signaling pathways of OCL formation in combination with RANKL. In preliminary studies we found that both RANKL and MIP-1d were capable of stimulating NF-?B and PLC?2 signaling, ..
  18. Hyeong Reh Choi Kim; Fiscal Year: 2016
    ..study unveiled exciting new roles of PDGF D in the regulation of osteoclast differentiation independent of the RANKL/RANK signaling axis as well as osteoblast differentiation involving modulation of homeoprotein expression...
  19. Effect of HIV Infection and HAART on Bone Homeostasis
    MERVYN NEALE WEITZMANN; Fiscal Year: 2013
    ..for bone resorption form under the influence of the key osteoclastogenic cytokine Receptor- Activator of NF-:B (RANKL)...
  20. Regulation of (Ca2+)i oscillation and osteoclast differentiation by RGS12
    Shuying Yang; Fiscal Year: 2010
    b>RANKL-evoked [Ca2+]i oscillations play a switch-on role in osteoclast differentiation through the NFAT2 activation pathway, however, the question remains as to how RANKL evokes the [Ca2+]j oscillation-NFAT2 pathway...
  21. Shp2 in Osteoclastogenesis and Bone Remodeling
    Wentian Yang; Fiscal Year: 2010
    ..evoked by macrophage-colony stimulating factor (M-CSF) and receptor activator of nuclear factor kB ligand (RANKL) regulated by Shp2 for osteoclastogenesis and osteoclast bone resorptive function...
  22. Xu Feng; Fiscal Year: 2016
    DESCRIPTION (provided by applicant): The receptor activator of NF-?B (RANK) ligand (RANKL), a member of the tumor necrosis factor (TNF) superfamily, plays an essential role in osteoclast (OC) formation, function and survival by binding ..
  23. DAP12 and ITAM-signals in Osteoclastogenesis
    Mary C Nakamura; Fiscal Year: 2013
    ..provide a Ca2+ signal to activate the critical transcription factor for osteoclastogenesis, NFATc1 during RANKL stimulation...
  24. ROLE OF CSF-1 IN OSTEOCLAST FUNCTION
    KARL LEONARD INSOGNA; Fiscal Year: 2013
    ..In the second Specific Aim, the role of BCA3 in mediating both CSF1 and RANKL signaling will be explored...
  25. MERVYN N WEITZMANN; Fiscal Year: 2016
    ..resorbing cells that form under the influence of the key osteoclastogenic cytokine Receptor- Activator of NF-:B (RANKL). RANKL activity is moderated by its physiological decoy receptor osteoprotegerin (OPG)...
  26. Gene-Engineered and Targeted Stem Cell Therapy for Myeloma
    Selvarangan Ponnazhagan; Fiscal Year: 2013
    ..bone resorption by triggering a coordinated increase in the receptor activator of nuclear factor-: B ligand (RANKL) and a decrease in osteoprotegerin (OPG) in the bone marrow...
  27. Cathespin K Radioligands for In Vivo Imaging
    Michael R Kilbourn; Fiscal Year: 2012
    ..osteoclast-dependent localization of radiotracers will be done in rats using focal skeletal injections of RANKL (receptor activator for nuclear facktorB ligand, to induce osteoclastogenesis) or osteoprotogerin (to inhibit ..
  28. Francis Young In Lee; Fiscal Year: 2016
    ..We previously confirmed the role of pERK1/2 on the production of pro-osteoclastogenic cytokines such as RANKL, MCSF, COX-2 and IL-1b...
  29. The Effect of PTHrP During Lactation
    John J Wysolmerski; Fiscal Year: 2010
    ..The first will test if PTHrP and estrogen withdrawal together, acting through stimulation of RANKL signaling, are sufficient to explain all bone loss during lactation...
  30. Amelioration of Immune Cell-Mediated Periodontal Disease
    Toshihisa Kawai; Fiscal Year: 2012
    ..of immune effector cells and/or regulating expression of the cytokine, Receptor Activator of NF-?B Ligand (RANKL)...
  31. Subburaman Mohan; Fiscal Year: 2014
    ..by which Cldn-18 regulates OC functions have revealed exciting preliminary data to suggest that Cldn-18 effects on RANKL signaling are mediated by a novel mechanism that is independent of its known tight junction function...
  32. Lionel B Ivashkiv; Fiscal Year: 2016
    ..Osteoclast differentiation is dependent on the TNF family member RANKL. During joint inflammation, inflammatory factors such as TNF and IL-1 increase osteoclast differentiation leading ..
  33. Functional Analysis of NHA-oc/NHA2 in vivo
    RICARDO ANIBAL BATTAGLINO; Fiscal Year: 2010
    ..Recently, we identified a gene, nha-oc/NHA2, which is strongly up-regulated during RANKL-induced osteoclast differentiation in vitro and in vivo...
  34. Joy Tsai; Fiscal Year: 2014
    ..of denosumab (DMAB), a monoclonal antibody that binds to receptor activator of nuclear factor-kB ligand (RANKL), and TPTD was recently reported to increase bone mineral density more than either drug alone...
  35. Function of Phospholipase Cgamma2 in RANKL-Induced Osteoclastogenesis
    Yabing Chen; Fiscal Year: 2010
    ..Receptor activator of NF?B ligand (RANKL) activates calcium signals that lead to activation of nuclear factor of activated T cells c1 (NFATc1), an ..
  36. Is Mitf the Missing Puzzle Linking NFATc1 to Osteoclastogenesis
    Yi Ling Lin; Fiscal Year: 2010
    ..recruit B and T cells from peripheral blood circulation, and these immune cells are the important local sources of RANKL, which promotes osteoclastogenesis, leading to chronic alveolar bone loss...
  37. Evaluation of a Novel Anti-Resorptive Therapy for Osteogenesis Imperfecta
    PATRICIA A COLLIN-OSDOBY; Fiscal Year: 2012
    ..Denosumab, is an excellent choice for investigation because it is a recently developed short-acting novel RANKL-specific human monoclonal antibody that represents a new type of anti-resorptive agent...
  38. Role of TNFa in Osteoclast-Mediated Bone Loss
    Lianping Xing; Fiscal Year: 2012
    ..the involvement of VEGF-C in this setting, we carried out a series preliminary studies and demonstrated that 1) RANKL and TNF induce VEGF-C expression in OCPs and OCs;2) VEGF-C stimulates osteoclastic bone resorption;3) RA joints ..
  39. Innate Immune Bacterial Recognition and Osteoclastogenesis
    Caroline A Genco; Fiscal Year: 2010
    ..tumor necrosis factor (TNF)-, interleukin (IL)-1, IL-6, and receptor activator of nuclear factor B ligand (RANKL) (54,94,104)...
  40. KIM CARPENTER MANSKY; Fiscal Year: 2016
    ..Further data indicate that these effects are mediated through RANKL-regulated interactions between HDAC7 and the MITF transcription factor...
  41. JULIA THERESE WARREN; Fiscal Year: 2014
    ..its function, both of which are downstream of signaling through the cytokine receptor activator of NF-kB ligand (RANKL)...
  42. Regulation of B-Cell Apoptosis by TLR Signaling in Periodontal Disease
    Xiaozhe Han; Fiscal Year: 2012
    ..are densely infiltrated at the site of infection and are a primary source of receptor activator of NF-:B ligand (RANKL), a cytokine that plays a pivotal role in osteoclast differentiation and inflammatory bone resorption...
  43. RANKL/OPG-Mediated Control of Vascular Calcification
    Linda L Demer; Fiscal Year: 2010
    ..Two of the major regulators are RANKL, a TNF-alpha superfamily member, and OPG, its soluble decoy receptor...
  44. KARL LEONARD INSOGNA; Fiscal Year: 2015
    ..completely inhibits the ability of myeloma cells to stimulate the formation of osteoclasts from DCs as well as RANKL/CSF1 induced osteoclastogenesis from normal marrow precursors...
  45. Brn3 Transcription Factor Family in Osteoclastogenesis
    ULRIKE CAROLINE SCHULZE-SPATE; Fiscal Year: 2013
    ..b>RANKL is a mandatory factor in inducing osteoclast differentiation, although the signaling pathways it activates are ..
  46. Haibo Zhao; Fiscal Year: 2015
    ..been shown to regulate cdc42, a small GTPase that is required for bone homeostasis in mice by modulating M-CSF and RANKL signaling...
  47. Kevin P McHugh; Fiscal Year: 2015
    ..are essential for physiologic bone resorption, are derived from hematopoietic precursors in response to M-CSF and RANKL. In vitro experiments examining gene expression profiles of OC precursors exposed to RANKL and M-CSF led to ..
  48. Mechanisms of RANKL Mediated Osteoclast Activation
    Steven L Teitelbaum; Fiscal Year: 2012
    ..Our overriding goal has been to detail the mechanisms by which cytokines, such as TNF, RANKL and M-CSF mediate bone loss...
  49. T-cell Mediation of Focal Bone Loss Induced by Transient Muscle Paralysis
    Brandon J Ausk; Fiscal Year: 2011
    ..transient muscle paralysis rapidly induces focal osteoclast mediated trabecular and cortical bone loss though a RANKL mediated process...
  50. The Role of Paxillin in the Osteoclast
    CARL DESELM; Fiscal Year: 2011
    ..Specifically, the paxillin knock out (Pax-/-) OC is larger and is more sensitive to RANKL (the main activating cytokine of the OC), yet its resorptive capacity is impaired...
  51. Bc12 regulates osteoclast survival
    Junro Yamashita; Fiscal Year: 2010
    ..Endogenous receptor activator for nuclear factor-kappa B ligand (RANKL) levels are comparable between Bcl2+/+ and Bcl2-/- in these cultures...
  52. Conor C Lynch; Fiscal Year: 2014
    ..and destruction, namely parathyroid related peptide (PTHrP), receptor activator of nuclear kappa B ligand (RANKL) and transforming growth factor beta (TGF[unreadable])...
  53. Francis Young In Lee; Fiscal Year: 2015
    ..We observed that PTH(1-34) was not inhibiting RANKL through osteoclast precursors, but was inhibiting pro-osteoclastogenic cytokines like MCSF in osteoblast cells...
  54. Yousef Abu-Amer; Fiscal Year: 2016
    ..In fact, we discovered recently that constitutive activation of IKK2 is sufficient to induce RANKL-independent osteoclastogenesis in vitro...
  55. Julia F Charles; Fiscal Year: 2016
    ..OCs differentiate from myeloid precursors under the influence of the cytokine RANKL, derived from osteocytes, activated T-cells or cytokine stimulated stromal cells...
  56. The Role of Osteoactivin in Osteoblast Development and Function
    Fayez F Safadi; Fiscal Year: 2013
    ..g. RANKL) by stromal cells/osteoblasts in the bone microenvironment...
  57. Erin Nevius; Fiscal Year: 2014
    ..differentiate from recirculating monocytes in niches adjacent to bone and require two critical signals, M-CSF and RANKL. How monocytes and osteoclast precursors migrate to the bone to interact with cells expressing the appropriate ..
  58. Yi Ping Li; Fiscal Year: 2016
    ..necessary to clarify why M-CSF alone induces precursors to differentiate into macrophages, while both M-CSF and RANKL induce precursors to differentiate into osteoclasts. Further study is needed to address these biological questions...
  59. Yang Yang; Fiscal Year: 2015
    ..The formation and function of bone resorbing osteoclasts is activated by Receptor Activator of NF-?B Ligand (RANKL) and inhibited by osteoprotegerin (OPG)...
  60. Osteoprotective Activity of a Dried Plum Extract
    Brenda J Smith; Fiscal Year: 2012
    ..and activity and inhibit osteoclastogenesis simultaneously by up-regulating Runx2 and down-regulating RANKL. To test this hypothesis the following specific aims have been developed: 1) To determine the fractions of DPE ..
  61. Regulatory T Cells and Tumor Bone Marrow Metastasis
    Weiping Zou; Fiscal Year: 2010
    ..Receptor activator of NF-kB (RANK) and its ligand RANKL signals are implicated in Treg expansion in diabetes and ultraviolet-induced immune suppression...
  62. REUBEN HAN KYU KIM; Fiscal Year: 2016
    ..The objectives of this proposal are: 1) to investigate role of RANKL, a secretory protein important for bone remodeling and healing, using genetically engineered mice;2) to identify ..
  63. RANK-Associated Inhibitor (RAIN) in Osteoclast Formation
    Bryant Darnay; Fiscal Year: 2007
    DESCRIPTION (provided by applicant): Receptor activator of NF-kappaB (RANK) and its ligand (RANKL, also known as TRANCE/ODF/OPGL) are essential mediators of osteoclastogenesis and have been implicated in various diseases, which include ..
  64. Erin L Ealba; Fiscal Year: 2015
    ..Specific Aim 3 will determine the extent to which NCM acts via TGF2-dependent RANKL/OPG signaling to affect osteoclast activity and jaw length...
  65. JONATHAN A SOBOLOFF; Fiscal Year: 2016
    ..resorption is the final common pathway in pathologic bone destruction, and Ca2+ signaling is critical to RANKL-stimulated osteoclastogenesis...
  66. Michael E Rosenfeld; Fiscal Year: 2016
    ..in mice that are deficient in osteoprotegerin, a decoy receptor for the receptor activator of NFkB ligand (RANKL). RANK-RANKL plays an essential role in bone homeostasis by stimulating the differentiation of osteoclasts...
  67. Osteoclastogenesis and RANK signaling to NF-kB via TRAF6
    JASON BOCH; Fiscal Year: 2005
    ..required factor for the differentiation and activation of osteoclasts is Receptor and Activator of NF-kB Ligand (RANKL) which mediates its effects via a specific cell surface receptor, Receptor and Activator of NF-kB (RANK)...
  68. Qing Yi; Fiscal Year: 2014
    ..these two cell lines produced significantly higher levels of receptor activator of nuclear factor ?B ligand (RANKL), TNF-a, and dickkopf-1 (DKK1)...
  69. Regulation of osteoclastogenesis by TRANCE
    Yongwon Choi; Fiscal Year: 2004
    ..Recently, others found that TRANCE is also expressed in osteoblasts and works as an osteoclast differentiation factor such that soluble TRANCE, in conjunction with M-CSF, can substitute for stromal cells to induce ..
  70. NAHID JAMAL RIANON; Fiscal Year: 2014
    ..Both AT1 and AT2 are expressed in bone cells and are linked with up-regulation of RANKL function resulting in high osteoclastogenic activity...
  71. TRAF6 E3 LIGASE FUNCTION IN OSTEOCLASTOGENESIS
    Bryant G Darnay; Fiscal Year: 2010
    ..The binding of RANKL to its receptor results in the recruitment of TRAF6, which activates the NF-(B, JNK, p38, and MAPK pathways...
  72. J Wesley Pike; Fiscal Year: 2016
    DESCRIPTION (provided by applicant): Receptor activator of NF-?B ligand (RANKL) is a TNF[unreadable]-type cytokine that is produced by mesenchymal lineage cells such as chondrocytes, osteoblasts and osteocytes, regulated by a number of ..
  73. Brendan F Boyce; Fiscal Year: 2016
    ..cytokines, such as TNF, are increased and drive osteoclast formation both directly and indirectly through RANKL and three sets of transcription factors: NF-?B;c-Fos;and NFATc1...
  74. The Role of AML1 in Osteoclastogenesis and Osteoclast Gene Expression
    Yi Ping Li; Fiscal Year: 2010
    ..1, NF-monstrated that AML1 is highly induced by RANKL and M-CSF together...
  75. EFFECTS OF ACID ON BONE
    David A Bushinsky; Fiscal Year: 2010
    ..also shown that in cultured bone, an increase in H+ induces a prostaglandin-dependent increase in osteoblastic RANKL leading to enhanced bone resorption...